CL2021001623A1 - Terapia de combinación con un inhibidor de raf y un inhibidor de cdk4/6 para utilizar en el tratamiento del cáncer - Google Patents

Terapia de combinación con un inhibidor de raf y un inhibidor de cdk4/6 para utilizar en el tratamiento del cáncer

Info

Publication number
CL2021001623A1
CL2021001623A1 CL2021001623A CL2021001623A CL2021001623A1 CL 2021001623 A1 CL2021001623 A1 CL 2021001623A1 CL 2021001623 A CL2021001623 A CL 2021001623A CL 2021001623 A CL2021001623 A CL 2021001623A CL 2021001623 A1 CL2021001623 A1 CL 2021001623A1
Authority
CL
Chile
Prior art keywords
inhibitor
cdk4
combination therapy
treating cancer
raf
Prior art date
Application number
CL2021001623A
Other languages
English (en)
Inventor
Giordano Caponigro
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of CL2021001623A1 publication Critical patent/CL2021001623A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se relaciona con una combinación farmacéutica que comprende (a) un inhibidor de Raf como se define en la presente, o una sal farmacéuticamente aceptable del mismo y (b) un inhibidor de CKD4/6, en particular ribociclib, particularmente para utilizar en el tratamiento de una enfermedad proliferativa, con preferencia melanoma o adenocarcinoma ductal pancreático.
CL2021001623A 2018-12-20 2021-06-17 Terapia de combinación con un inhibidor de raf y un inhibidor de cdk4/6 para utilizar en el tratamiento del cáncer CL2021001623A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862782767P 2018-12-20 2018-12-20
US201962793128P 2019-01-16 2019-01-16

Publications (1)

Publication Number Publication Date
CL2021001623A1 true CL2021001623A1 (es) 2022-02-11

Family

ID=69165429

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2021001623A CL2021001623A1 (es) 2018-12-20 2021-06-17 Terapia de combinación con un inhibidor de raf y un inhibidor de cdk4/6 para utilizar en el tratamiento del cáncer

Country Status (12)

Country Link
EP (1) EP3897591A1 (es)
JP (1) JP2022514056A (es)
KR (1) KR20210105388A (es)
CN (1) CN113453671A (es)
AU (1) AU2019407159A1 (es)
BR (1) BR112021011699A2 (es)
CA (1) CA3123510A1 (es)
CL (1) CL2021001623A1 (es)
IL (1) IL283937A (es)
MX (1) MX2021007477A (es)
TW (1) TW202038964A (es)
WO (1) WO2020128878A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2017329090B9 (en) 2016-09-19 2019-09-05 Novartis Ag Therapeutic combinations comprising a RAF inhibitor and a ERK inhibitor
JP7309614B2 (ja) 2017-05-02 2023-07-18 ノバルティス アーゲー 組み合わせ療法
CN115551509A (zh) * 2020-05-12 2022-12-30 诺华股份有限公司 包含craf抑制剂的治疗组合

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR091876A1 (es) * 2012-07-26 2015-03-04 Novartis Ag Combinaciones farmaceuticas para el tratamiento de enfermedades proliferativas
US9242969B2 (en) 2013-03-14 2016-01-26 Novartis Ag Biaryl amide compounds as kinase inhibitors
US20180250302A1 (en) * 2015-08-28 2018-09-06 Giordano Caponigro Combination of ribociclib and dabrafenib for treating or preventing cancer
JP7309614B2 (ja) * 2017-05-02 2023-07-18 ノバルティス アーゲー 組み合わせ療法

Also Published As

Publication number Publication date
CN113453671A (zh) 2021-09-28
IL283937A (en) 2021-07-29
CA3123510A1 (en) 2020-06-25
TW202038964A (zh) 2020-11-01
BR112021011699A2 (pt) 2021-09-08
KR20210105388A (ko) 2021-08-26
JP2022514056A (ja) 2022-02-09
MX2021007477A (es) 2021-08-05
EP3897591A1 (en) 2021-10-27
AU2019407159A1 (en) 2021-07-15
WO2020128878A1 (en) 2020-06-25

Similar Documents

Publication Publication Date Title
CL2023000846A1 (es) Terapia de combinación que incluye inhibidor de krasg12c y agente farmacéuticamente activo para tratar cáncer
CL2021001623A1 (es) Terapia de combinación con un inhibidor de raf y un inhibidor de cdk4/6 para utilizar en el tratamiento del cáncer
CL2018001152A1 (es) Composiciones y métodos para el tratamiento del cáncer
CO2017011197A2 (es) Terapia de combinación fgfr/pd-1 para el tratamiento del cancer
BR112018073920A2 (pt) inibidores de pd-1/pd-l1 para tratamento de câncer".
AR102553A1 (es) Terapia de combinación con agonistas de unión ox40 e inhibidores de tigit
CL2018000706A1 (es) Derivados de pirazolopirimidina como inhibidores btk para el tratamiento del cancer.
CL2017002996A1 (es) Compuestos alqueno tetrasustituidos y su uso
CR20170014A (es) Métodos para tratar el cáncer con inhibidores de tigit y agentes contra el cáncer
CO2017007662A2 (es) Terapias de combinación para el tratamiento de cánceres
AR107871A1 (es) Combinaciones de inhibidores de lsd1 para su uso en el tratamiento de tumores sólidos
BR112018013733A2 (pt) combinações anti-cd20 para o tratamento de tumores a
NI201400111A (es) Tratamiento del cáncer con inhibidores tor cinasa
AR101740A1 (es) Terapia de combinación y composiciones
BR112017018964A2 (pt) uso de plinabulin e métodos para tratar tumor cerebral
CR20170036A (es) Inhibidores de la proteína quinasa c y métodos de su uso
AR112144A1 (es) Compuestos para el tratamiento del sarcoma
BR112018008882A8 (pt) método para tratar um distúrbio proliferativo e produto farmacêutico
MX2020001727A (es) Terapia de combinacion.
CL2020001888A1 (es) Terapia de combinación para tratar o prevenir el cáncer.
CO2020001107A2 (es) Moduladores terapéuticos del modo inverso de la atp sintasa
CO2019003865A2 (es) Proteína terapéutica
CL2020002637A1 (es) Métodos de tratamiento de cáncer.
CL2020000270A1 (es) Combinación terapéutica de un inhibidor tirosina quinasa del egfr de tercera generación y un inhibidor raf.
CO2020004984A2 (es) Proceso para preparar el benzotiofen-2-il boronato